Viral peptide–MHC class I complex (None established; occasionally "pMHC-I" or "pMHC class I" is used in scientific literature)

The **viral peptide–MHC class I complex** is a transient molecular assembly central to adaptive immunity, consisting of a short peptide (8–10 amino acids) derived from viral proteins and a major histocompatibility complex class I (MHC-I) molecule—typically HLA class I in humans. The complex forms when viral proteins are degraded in the cytosol and the resulting peptides are translocated into the endoplasmic reticulum via the TAP transporter. Within the ER, the peptides are loaded onto the peptide-binding groove of the MHC-I molecule, aided by a network of chaperones and the peptide-loading complex (PLC)[2][4][7]. The stable peptide–MHC class I complex is then transported to the cell surface and presented to cytotoxic T lymphocytes (CD8+ T cells), enabling immune recognition and destruction of virus-infected or transformed cells by induction of apoptosis[1][3][5][6]. The structural basis of this complex's specificity rests on the highly polymorphic nature of MHC-I alleles and their binding pockets, which determine peptide repertoire and CTL recognition[2][4][9]. The function of this complex is essential for distinguishing self from non-self and for orchestrating cell-mediated immune responses against viral infections and cancer[1][3][5][6][7][8][9]. Failure of peptide–MHC I assembly or downregulation by viruses and tumor cells is a common immune evasion strategy and represents a key challenge in immunotherapy[1][5]. This complex does not represent a druggable receptor in the classical sense, but is a molecular target for vaccine design, T cell-based therapies, and as a biomarker for cellular immune activity in infectious diseases, oncology, and transplantation medicine[5][8].

Other names

Peptide–MHC class I complexpMHC class Iviral antigen–MHC class I complexMHC-I:peptide complexHLA-I:peptide complex (in humans)

Enhancement of CTL response by increasing presentation of specific antigenic peptides; Modulation of immune tolerance or activation (e.g., cancer immunotherapy, infectious disease vaccine); Blockade or alteration of TCR–pMHC interaction (rare, mostly experimental).